161 related articles for article (PubMed ID: 34496154)
1. Cabazitaxel suppresses colorectal cancer cell growth via enhancing the p53 antitumor pathway.
Zhang W; Sun R; Zhang Y; Hu R; Li Q; Wu W; Cao X; Zhou J; Pei J; Yuan P
FEBS Open Bio; 2021 Nov; 11(11):3032-3050. PubMed ID: 34496154
[TBL] [Abstract][Full Text] [Related]
2. RASSF10 suppresses colorectal cancer growth by activating P53 signaling and sensitizes colorectal cancer cell to docetaxel.
Guo J; Yang Y; Yang Y; Linghu E; Zhan Q; Brock MV; Herman JG; Zhang B; Guo M
Oncotarget; 2015 Feb; 6(6):4202-13. PubMed ID: 25638156
[TBL] [Abstract][Full Text] [Related]
3. The small molecule AU14022 promotes colorectal cancer cell death via p53-mediated G2/M-phase arrest and mitochondria-mediated apoptosis.
Ryu H; Nam KY; Kim JS; Hwang SG; Song JY; Ahn J
J Cell Physiol; 2018 Jun; 233(6):4666-4676. PubMed ID: 29030986
[TBL] [Abstract][Full Text] [Related]
4. CTCF promotes colorectal cancer cell proliferation and chemotherapy resistance to 5-FU via the P53-Hedgehog axis.
Lai Q; Li Q; He C; Fang Y; Lin S; Cai J; Ding J; Zhong Q; Zhang Y; Wu C; Wang X; He J; Liu Y; Yan Q; Li A; Liu S
Aging (Albany NY); 2020 Jul; 12(16):16270-16293. PubMed ID: 32688344
[TBL] [Abstract][Full Text] [Related]
5. 8-Acetonyldihydronitidine inhibits the proliferation of human colorectal cancer cells via activation of p53.
Zhou J; Li Z; Zhang J; Wang H; Yin S; Du J
Eur J Pharmacol; 2019 Jul; 854():256-264. PubMed ID: 30928633
[TBL] [Abstract][Full Text] [Related]
6. A selective p53 activator and anticancer agent to improve colorectal cancer therapy.
Ramos H; Soares MIL; Silva J; Raimundo L; Calheiros J; Gomes C; Reis F; Monteiro FA; Nunes C; Reis S; Bosco B; Piazza S; Domingues L; Chlapek P; Vlcek P; Fabian P; Rajado AT; Carvalho ATP; Veselska R; Inga A; Pinho E Melo TMVD; Saraiva L
Cell Rep; 2021 Apr; 35(2):108982. PubMed ID: 33852837
[TBL] [Abstract][Full Text] [Related]
7. Anticancer bioactive peptides suppress human colorectal tumor cell growth and induce apoptosis via modulating the PARP-p53-Mcl-1 signaling pathway.
Su LY; Shi YX; Yan MR; Xi Y; Su XL
Acta Pharmacol Sin; 2015 Dec; 36(12):1514-9. PubMed ID: 26592508
[TBL] [Abstract][Full Text] [Related]
8. Helveticoside Exhibited p53-dependent Anticancer Activity Against Colorectal Cancer.
An N; Sun Y; Ma L; Shi S; Zheng X; Feng W; Shan Z; Han Y; Zhao L; Wu H
Arch Med Res; 2020 Apr; 51(3):224-232. PubMed ID: 32147288
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the MEK Inhibitor Cobimetinib and its Potential Application to Colorectal Cancer Cells.
Gong S; Xu D; Zhu J; Zou F; Peng R
Cell Physiol Biochem; 2018; 47(2):680-693. PubMed ID: 29794421
[TBL] [Abstract][Full Text] [Related]
10. Gypenosides Synergistically Enhances the Anti-Tumor Effect of 5-Fluorouracil on Colorectal Cancer In Vitro and In Vivo: A Role for Oxidative Stress-Mediated DNA Damage and p53 Activation.
Kong L; Wang X; Zhang K; Yuan W; Yang Q; Fan J; Wang P; Liu Q
PLoS One; 2015; 10(9):e0137888. PubMed ID: 26368019
[TBL] [Abstract][Full Text] [Related]
11. Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and -resistant colorectal cancer cells.
Wen C; Chen J; Zhang D; Wang H; Che J; Qin Q; He L; Cai Z; Lin M; Lou Q; Huang L; Chen D; Iwamoto A; Ren D; Wang L; Lan P; Wang J; Liu H; Yang X
Cancer Lett; 2016 Dec; 383(2):295-308. PubMed ID: 27713084
[TBL] [Abstract][Full Text] [Related]
12. SKLB316, a novel small-molecule inhibitor of cell-cycle progression, induces G2/M phase arrest and apoptosis in vitro and inhibits tumor growth in vivo.
Xia Y; Lei Q; Zhu Y; Ye T; Wang N; Li G; Shi X; Liu Y; Shao B; Yin T; Zhao L; Wu W; Song X; Xiong Y; Wei Y; Yu L
Cancer Lett; 2014 Dec; 355(2):297-309. PubMed ID: 25301449
[TBL] [Abstract][Full Text] [Related]
13. Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor.
Wu T; Chen W; Zhong Y; Hou X; Fang S; Liu CY; Wang G; Yu T; Huang YY; Ouyang X; Li HQ; Cui L; Yang Y
Mol Cancer Ther; 2017 Apr; 16(4):717-728. PubMed ID: 27903750
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of curcumin on the proliferation, migration and apoptosis of human colorectal carcinoma HCT‑116 cells.
Xiang L; He B; Liu Q; Hu D; Liao W; Li R; Peng X; Wang Q; Zhao G
Oncol Rep; 2020 Nov; 44(5):1997-2008. PubMed ID: 33000266
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor effect of 3-bromopyruvate and 5-fluorouracil against human colorectal cancer through cell cycle arrest and induction of apoptosis.
Chong D; Ma L; Liu F; Zhang Z; Zhao S; Huo Q; Zhang P; Zheng H; Liu H
Anticancer Drugs; 2017 Sep; 28(8):831-840. PubMed ID: 28816773
[TBL] [Abstract][Full Text] [Related]
16. Decreasing CNPY2 Expression Diminishes Colorectal Tumor Growth and Development through Activation of p53 Pathway.
Yan P; Gong H; Zhai X; Feng Y; Wu J; He S; Guo J; Wang X; Guo R; Xie J; Li RK
Am J Pathol; 2016 Apr; 186(4):1015-24. PubMed ID: 26835537
[TBL] [Abstract][Full Text] [Related]
17. Synthetic antiprotozoal thiazolide drug induced apoptosis in colorectal cancer cells: implications of IL-6/JAK2/STAT3 and p53/caspases-dependent signaling pathways based on molecular docking and in vitro study.
Tantawy MA; El-Sherbeeny NA; Helmi N; Alazragi R; Salem N; Elaidy SM
Mol Cell Biochem; 2020 Jun; 469(1-2):143-157. PubMed ID: 32356241
[TBL] [Abstract][Full Text] [Related]
18. 5-FU promotes stemness of colorectal cancer via p53-mediated WNT/β-catenin pathway activation.
Cho YH; Ro EJ; Yoon JS; Mizutani T; Kang DW; Park JC; Il Kim T; Clevers H; Choi KY
Nat Commun; 2020 Oct; 11(1):5321. PubMed ID: 33087710
[TBL] [Abstract][Full Text] [Related]
19. Cisatracurium-induced proliferation impairment and death of colorectal cancer cells, HCT116 is mediated by p53 dependent intrinsic apoptotic pathway in vitro.
Yabasin IB; Lu Z; Yu JC; Wen Q
Biomed Pharmacother; 2017 Jul; 91():320-329. PubMed ID: 28463795
[TBL] [Abstract][Full Text] [Related]
20. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism.
Pereira DM; Simões AE; Gomes SE; Castro RE; Carvalho T; Rodrigues CM; Borralho PM
Oncotarget; 2016 Jun; 7(23):34322-40. PubMed ID: 27144434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
